Artemisia annua and Artemisia afra tea infusions vs. artesunate-amodiaquine (ASAQ) in treating Plasmodium falciparum malaria in a large scale, double blind, randomized clinical trial

Jérôme Munyangia, Lucile Cornet-Vernet, Michel Idumbo, Chen Lu, Pierre Lutgen, Christian Perronne, Nadège Ngombe, Jacques Bianga, Bavon Mupenda, Paul Lalukala, Guy Mergeai, Dieudonné Mumba, Melissa Towler, Pamela Weathers

A Faculté de Médecine Université de Kolwezi-Lualaba, Congo DRC
B Vice Présidente de La Maison de l’Artemisia(association Loi 1901), 20 rue Pierre Demours, 75017 Paris, France
C Centre de Santé de Lubile, Maniema, Congo DRC
D Department of Mathematics, Worcester Polytechnic Institute, USA
E Association IFVB-BELHERB, Luxembourg
F Faculté de Médecine de Paris IDF Ouest, France
G Faculté de Pharmacie, Université de Kinshasa, Congo DRC
H Programme National Lutte Contre le Paludisme, Maniema, Congo DRC
I Ecole de Santé publique Université de Kinshasa, Congo DRC
J Ministère Provincial de Santé Publique Maniema, Congo DRC
K Université de Liège, Belgium
L Faculté de Médecine Université de Kinshasa, Congo DRC
M Department of Biology and Biotechnology, Worcester Polytechnic Institute, USA

ARTICLE INFO

Keywords:
ACT
ASAQ
Artemisinin
Malaria
Clinical trial
Tea infusion

ABSTRACT

Background and objective: Prior small-scale clinical trials showed that Artemisia annua and Artemisia afra infusions, decoctions, capsules, or tablets were low cost, easy to use, and efficient in curing malaria infections. In a larger-scale trial in Kalima district, Democratic Republic of Congo, we aimed to show A. annua and/or A. afra infusions were superior or at least equivalent to artesunate-amodiaquine (ASAQ) against malaria.

Methods: A double blind, randomized clinical trial with 957 malaria-infected patients had two treatment arms: 472 patients for ASAQ and 471 for Artemisia (248 A. annua, 223 A. afra) remained at end of the trial. ASAQ-treated patients were treated per manufacturer posology, and Artemisia-treated patients received 1 l/d of dry leaf/twig infusions for 7 d; both arms had 28 d follow-up. Parasitemia and gametocytes were measured microscopically with results statistically compared among arms for age and gender.

Results: Artemisinin content of A. afra was negligible, but therapeutic responses of patients were similar to A. annua-treated patients; trophozoites cleared after 24 h, but took up to 14 d to clear in ASAQ-treated patients. D28 cure rates defined as absence of parasitemia were for pediatrics 82, 91, and 50% for A. afra, A. annua and ASAQ; while for adults cure rates were 91, 100, and 30%, respectively. Fever clearance took 48 h for ASAQ, but 24 h for Artemisia. From D14-28 no Artemisia-treated patients had microscopically detectable gametocytes, while 10 ASAQ-treated patients remained gametocyte carriers at D28. More females than males were gametocyte carriers in the ASAQ arm but were unaffected in the Artemisia arms. Hemoglobin remained constant at 11 g/dl for A. afra after D1, while for A. annua and ASAQ it decreased to 9–9.5 g/dl. Only 5.0% of Artemisia-treated patients reported adverse effects, vs. 42.8% for ASAQ.

Conclusion: A. annua and A. afra infusions are polytherapies with better outcomes than ASAQ against malaria. In contrast to ASAQ, both Artemisias appeared to break the cycle of malaria by eliminating gametocytes. This study merits further investigation for possible inclusion of Artemisia tea infusions as an alternative for fighting and eradicating malaria.

Abbreviations: ACT, artemisinin combination therapy; ASAQ, artesunate-amodiaquine; DLA, dried leaf Artemisia; i.v., intravenous; PNLP, programme national de Lutte contre le Paludisme

*Corresponding author.
E-mail address: lcv@maison-artemisia.org (L. Cornet-Vernet).

Received 5 January 2018; Received in revised form 29 November 2018; Accepted 1 December 2018
0944-7113/ © 2018 Elsevier GmbH. All rights reserved.
Background

The Democratic Republic of Congo (DRC) has one of the highest malaria rates. In 2016 >50,000 people died, mainly children (WHO, 2017 http://apps.who.int/iris/bitstream/10665/259492/1/9789241565523-eng.pdf). Maniema province is a holo-endemic zone with >80% of the population infected (Programme National de Lutte contre le Paludisme, 2015. Rapport Malaria. Kinshasa, RDC; PNLP). In 2005, Artemisinin Combination Therapy (ACT) became the first line treatment for all in the DRC.

*Artemisia annua* L. and *Artemisia afra* Jacq. ex Willd., of Chinese and South African origin, respectively, were used for centuries medicinally as infusions or powders to treat malaria (Willcox et al., 2004; Weathers et al., 2014; Liu et al., 2010). Both showed *in vitro* efficacy against *Plasmodium falciparum* (Kraft et al., 2003; Moyo et al., 2016; Gathirwa et al., 2007; Liu et al., 2010). For generations, *A. afra* was an integral part of the pharmacopeia in many regions of DRC and other areas of eastern and southern Africa (FAO Forestry paper 67: 68-73, Rome. http://www.fao.org/docrep/015/an797e/an797e00.pdf). In recent case studies, administration of dried *A. annua* leaf tablets successfully cured 18 patients with severe malaria who did not respond to therapy with ACT (artemether-lumefantrine) and i.v. artemesunate (Daddy et al., 2017).

Medicinal plants represent the main, if not the only treatment accessible to much of humanity (WHO, 2014 http://www.who.int/medicines/publications/traditional/trm_strategy14_23/en/) and may offer a low cost and potentially more widely available alternative to ACTs. *A. annua* is grown in commercial plantations and by small stakeholder farmers in at least 39 countries, 33 of which are in Africa (Supplemental Material). For traditional medicine, WHO provided guidelines (WHO, 2000 http://apps.who.int/iris/bitstream/10665/66783/1/WHO_EDM_TRM_2000.1.pdf) and encouraged studies and clinical trials on herbal medicines (WHO, 2014). Subsequently, we launched a large-scale clinical trial aimed at confirming encouraging results from smaller-scale trials in Africa and South America with *A. annua* and *A. absinthium*. In those small trials cure rates of >95% were reported (Mueller et al., 2000; Gebeyaw et al., 2010; Chougouo et al., 2012; Zime-Diawara et al., 2015).

Methods

**Plant material, handling and phytochemical analysis**

Field-grown leaves and twigs of *Artemisia annua* L. and *Artemisia afra* Jacq. ex Willd. (Asteraceae) were collected in France (PAR), Senegal (SEN), Burundi (BUR), and Luxembourg (LUX) and processed as described in Munyangi et al. (2018) where voucher ids also are listed. Artemisinin was measured using gas chromatography mass spectroscopy (GCMS) instead of HPLC to avoid artemisinin false positives (Smith et al., 2010). Extraction and assay methods for phytochemical compounds are detailed in Munyangi et al. (2018) where phytochemical contents of both *Artemisia* sp. are documented: *A. annua* had 1.34–1.70 mg artemisinin/g dry weight; *A. afra* had 0.036 mg artemisinin/g dry weight.

**Study design**

The study was done in 2015 in Kalima health district, Pangi zone, Maniema province, in five areas: Kakutya, Kinkungwa, Kamundala, Lubile, and Kakozwa (for location map see supplemental material of Munyangi et al., 2018). Patients with uncomplicated malaria were enrolled in the three arms of the trial (Fig. 1) October to December 2015. The research protocol was registered and approved by the Comité d’Ethique de l’ Ecole de Santé Publique de Kinshasa (MIN.RST/SG/180/001/2016) acting for the DRC Ministry of Health. All adult patients provided written consent to participate in the trial; minor patients were signed by parents. The study followed guidelines of the Declaration of Helsinki and Tokyo for humans.

**Criteria for inclusion of patients**

Patients were recruited by passive case finding. Eligibility of patients was restricted to adults or children ≥ 5 y with axillary temperature of ≥ 37.5 °C and parasitemia of 2000 – 200,000 trophozoites/μl. Patients with these symptoms were excluded: severe malaria, undernourishment, repetitive vomiting ± diarrhea, other concomitant

---

**Fig. 1.** Trial design.
infectious disease, known allergy to ACTs, pregnancy or breast feeding, cardiac, hepatic, or renal deficiencies. We also excluded patients treated with antimalarial drugs within 7 d preceding the trial or with antibiotics that might have antimalarial effects. Patients were enrolled and distributed randomly into a treatment arm (Fig. 1). Demographics of the study group are in Table 1. Drugs were distributed in numbered opaque envelopes selected randomly by each patient. Clinical symptoms of enrolled patients are shown in Table S1.

**Clinical and laboratory analyses**

According to WHO procedures, a rapid diagnostic test (RDT) confirmed malarial infection. Kalima health district is a sentinel surveillance zone for malaria, so SDBioline Malaria Ag P.f./Pan test (batch nr 05FK60) was used on D0 for all patients. Thick and thin blood smears were microscopically analyzed for trophozoites and gametocytes, respectively. Trophozoites were measured per μl of blood; gametocytes were noted as present or absent to determine number of carriers. In each trial area, slides were scrutinized by two independent laboratories. In case of dubious or conflicting results, a PNLP expert was consulted. A random 10% of slides collected at different stages of the trial were quality-control checked by a third party. Hemoglobin level, asexual parasites, and presence of gametocytes were measured on D0. Hemoglobin was measured spectrophotometrically at 540 nm using Drabkin’s Reagent at the peripheral health centers. Hemoglobin was also measured at the reference laboratory via hemoglobin analyzer; to settle value discrepancies, the reference lab value was used. After testing, patients were administered their first drug dose and a capillary blood sample was collected, dried on Whatman grade 3 filter paper, and stored for eventual genotyping. Patient follow-up including thick and thin blood smears was at D 1, 2, 3, 4, 7, 14, 21, and 28 post trial enrollment. From D0–D7, patients were treated in hospital to insure therapeutic compliance. Alanine (ALAT) and aspartate (ASAT) liver transaminases also were measured using the method of Reitman and Frankel (1957).

**Drug administration**

Artesunate-amodiaquine (ASAQ Winthrop, Sanofi–Aventis) was administered as tablets 25 mg/67.5 mg, 50 mg/135 mg, and 100 mg/270 mg. Manufacturer posology was: 4 mg of artesunate and 10 mg of amodiaquine/kg, once daily for 3 d, followed by ASAQ placebo tablets for the remaining 4 d. In the Artemisia arm, patients drank 0.33 l of infusion every 8 h for 7 d. In the Artemisia arm infusion every 8 h for 7 d Infusion preparation was: 5 g of dried leaves and twigs of A. annua or A. afra infusion every 8 h for 7 d Preparation was: 5 g of dried leaves and twigs of A. annua or A. afra infusion every 8 h for 7 d Infusion preparation was: 5 g of dried leaves and twigs of A. annua or A. afra to 11 of boiling water, infuse for 10 min, and filter through sterilized 1 mm mesh. Pediatrics and adults received the same amount of Artemisia tea infusion; there was no adjustment for body weight.

The trial was double blinded as detailed in Munyangi et al. (2018). Briefly, A. annua and A. afra arms received the infusion plus ASAQ placebo from D1 to 7. The ASAQ arm received ASAQ tablets on D1–3 followed by ASAQ placebo on D4–7; these same patients also received Artemisia placebo from D1–7. ASAQ placebo consisted of pill-shaped saccharose/glucose tablets purchased in a pharmacy. To conceive a placebo for Artemisia infusion was more challenging. WHO suggested using the drug at very low dose, so A. annua and A. afra placebos contained 0.2 g/l of plant material and patients drank placebo infusion of one Artemisia species or the other. All trial personnel were unaware of arm assignments.

All treatments were administered inside health facilities and under medical control. In case of vomiting 30 min post-administration, the same drug was re-administered. For vomiting 60 min post-administration, no new administration took place. In case of persistent vomiting, the patient was excluded from the trial and their infection separately treated. Adverse events were recorded and defined by clinical observations and patient self-reporting.

**Concomitant treatment**

Medical treatment that did not violate trial exclusion criteria was maintained for patients having a known disease other than malaria at the beginning of the trial.

**Management and statistical analysis of data**

All data were initially recorded by hand in clinic notebooks, then transferred to an Excel file. Proportions were compared using chi-square test or Fisher exact test. Continuous and normally distributed data were compared by analysis of variance (ANOVA) and Student’s t-test. Other non-normally distributed data were compared by Mann–Whitney U test. Survival analyses, fever clearance time, and the parasite clearance time used the Kaplan–Meier method with two-sided log-rank statistics. No significant differences were seen among the five sites, so the data were pooled. Data were analyzed using SPSS for Windows version 1.0.0.903 and R for Windows version 3.4.2. P-values < 0.05 were considered statistically significant.

**Results and discussion**

This trial was conducted as a superiority trial. Where equivalence was noted, it was so stated. The primary outcome of the trial was that, based on microscopic analyses, both Artemisia sp. cured malaria faster and more effectively than ASAQ. The secondary outcomes were that compared to ASAQ, Artemisia-treated patients also had microscopically undetectable gametocytes and fewer adverse side effects.

**Clinical admission characteristics:** There were 943 patients who completed the trial with 258 pediatrics in each of the ASAQ and A. annua arms (Table 1). The median age was 29 y in the ASAQ group, 19 y in the A. annua group and 25 y in the A. afra group (Table 2); ages within each group ranged from 6 to 50 y. Of these, 67.7% were male, 32.3% were female; 41.1% were pediatrics and 58.9% adults in the A. annua group. In the A. afra group, 70.9% were male, 29.1% were female; 22.9% were pediatricians and 77.1% adults. In the ASAQ group, 65.3% were male, 34.7% were female; 22.3% were pediatrics and 77.7% adults. Of the five study sites, three included all three treatment arms, one had A. annua and ASAQ; the other had A. afra and ASAQ (Table 2). At admission parasitemia was >33,000 trophozoites/μl for all treatment arms.

**Fever and parasitemia progression:** Cures rates were established by D28 parasitemia. Compared to ASAQ-treated patients with an overall 34.3% cure by D28, A. afra and A. annua -treated patients were 88.8 and 96.4% cured, respectively (Table 3). Cures for ASAQ-treated

<table>
<thead>
<tr>
<th>Treatment arm</th>
<th>Gender</th>
<th>Age</th>
<th>5 y</th>
<th>6-15 y</th>
<th>&gt; 15 y</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. annua</td>
<td>Male (%)</td>
<td>168 (67.7%)</td>
<td>0</td>
<td>102 (41.1%)</td>
<td>146 (58.9%)</td>
</tr>
<tr>
<td>A. afra</td>
<td>Female (%)</td>
<td>80 (32.3%)</td>
<td>0</td>
<td>51 (22.9%)</td>
<td>172 (77.1%)</td>
</tr>
<tr>
<td>ASAQ</td>
<td>Male (%)</td>
<td>158 (70.9%)</td>
<td>0</td>
<td>105 (22.3%)</td>
<td>367 (77.7%)</td>
</tr>
<tr>
<td></td>
<td>Female (%)</td>
<td>65 (29.1%)</td>
<td>0</td>
<td>51 (22.9%)</td>
<td>172 (77.1%)</td>
</tr>
</tbody>
</table>

Table 1: Demographics of the Artemisia and ASAQ trial arms at time of enrollment (D0).
patients were 49.5% for pediatrics (ages 5–15 y) and 30.0% for adults (ages 16–65) (Table 3). Pediatric cures for A. annua and A. afra-treated patients were 91.2% and 82.4%, respectively, while for adults, cures were 100 and 90.7%, respectively (Table 3). There were 344 patients with parasites at D28; 9 for A. annua, 25 for A. afra, and 310 for ASAQ. Due to degradation of stored blood samples, we were unable to conduct a valid PCR analysis of the D28 patients with parasitemia. Considering the large number of D28 patients with parasitemia, a thorough PCR analysis is needed in future studies.

Fever clearance took 24 h in the Artemisia arm and 48 h for ASAQ (Fig. 2). Zime-Diawara et al. (2015) noticed total apyrexia even faster, only 12 h post-first Artemisia infusion. Using the log-rank test, p values were all significantly different among all four measured groups: both Artemisia vs. ASAQ; A. annua vs. A. afra; A. annua vs. ASAQ; A. afra vs. ASAQ.

On D1, parasitemia decreased 97.7% in the Artemisia arm and 85.2% for ASAQ. In both Artemisia arms, parasitemia totally cleared on D2 (Fig. 3). In the ASAQ arm, however, parasites remained in some patients until D14. By the log-rank test at D28, three of the four compared groups were significantly different, but there was no significant difference between A. annua and A. afra (p = 0.505). These results are similar to Zime-Diawara et al. (2015) with 108 patients receiving 1 l/d of 12 g/l Artemisia infusion. Parasitemia disappeared in all patients after 36 h, with excellent clinical tolerance. In a similar 48-patient study, Mueller et al. (2004) observed trophozoite disappearance by D4 for 92% of patients. Our Artemisia-treated patients were 96.4% cured on D28; only 5% of patients showed side effects, which was significantly better than ASAQ-treated patients with 42.8% adverse side effects (Table 4).

Patients treated with ASAQs received weight-adjusted amounts of artemesin ranging from 147.2 to 1293 mg in toto. Patients treated with A. afra received a maximum amount of artemisinin of 1.26 mg, while those treated with A. annua received 46.9 mg (BUR) or 59.5 mg (LUX) in toto; there was no weight adjustment. This was 3-1000 fold less artemisinin vs. ASAQs, yet Artemisia therapeutic outcome was better. This was consistent with recent case studies (Daddy et al., 2017) demonstrating efficacy of A. annua compressed leaf tablets (DLA) in treating patients unresponsive to either ASAQ or L. v. artemesina. The treatment course of DLA used in that study provided 55 mg maximum artemisinin to adults; for pediatrics, it was as low as 13.75 mg. These results collectively suggest other phytochemicals in the plants were crucial to the potent therapeutic outcome of the Artemisias.

Gametocyte elimination: D0 gametocyte carriers present in ASAQ-treated patients declined beginning on D7 post-treatment; by D28 only 10 of 472 patients were detectable carriers (Fig. 4). In contrast, no gametocyte carriers were detected in either Artemisia treatment from D14 onwards suggesting that both Artemisia, but not ASAQ, eliminated gametocytes. Gametocyte carriage was completely eliminated in all age groups treated with Artemisia (Table 5). In ASAQ-treated patients, both pediatric and adult patients still had microscopically detectable gametocytes at D28 (Table 5). Microscopic analysis underestimates gametocyte counts by several fold (Babiker and Schneider 2008), so future studies should use nested PCR to further probe for the presence of gametocytes in Artemisia-treated patients.

Gender differences occurred in the ASAQ group. There were 326 males in the Artemisia arm and 308 in the ASAQ arm, and 145 females in the Artemisia arm and 164 in the ASAQ arm. While both genders responded equally well to Artemisia, there was significantly more gametocyte carriage in females than males in the ASAQ-treated arm for D14–28 (Fishier’s Exact test, p = 0.012; data not shown). There was no differential age response in females. Artemisia-treated male carriers were significantly different at D2–4 but not at D7–28. Overall, these results indicated that Artemisia were better than ASAQ at removing gametocytes in females.

Hemoglobin improvement by A. afra, but not ASAQ or A. annua: While hemoglobin at D0, 1, 3, and 4 between A. annua and ASAQ was not statistically different (post hoc test, p > 0.05), between A. annua and A. afra there was a significant difference (Fig. 5). Hemoglobin remained

### Table 2

<table>
<thead>
<tr>
<th>Arm</th>
<th>Median (y)</th>
<th>Site average patient age (y)</th>
<th>Kakuyu</th>
<th>Kinkungwa</th>
<th>Kamundala</th>
<th>Lubile</th>
<th>Kakanwa</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. annua</td>
<td>19</td>
<td></td>
<td>22</td>
<td>25</td>
<td>24</td>
<td>nm</td>
<td>20</td>
</tr>
<tr>
<td>A. afra</td>
<td>25</td>
<td></td>
<td>28</td>
<td>27.5</td>
<td>nm</td>
<td>26.5</td>
<td>13.5</td>
</tr>
<tr>
<td>ASAQ</td>
<td>29</td>
<td></td>
<td>32</td>
<td>29.5</td>
<td>32</td>
<td>23</td>
<td>21</td>
</tr>
<tr>
<td>Overall</td>
<td>26</td>
<td></td>
<td>26</td>
<td>28.5</td>
<td>28</td>
<td>25</td>
<td>19.5</td>
</tr>
</tbody>
</table>

Not all test sites included both Artemisias; na, not applicable; nm, not measured at that site.

### Table 3

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>D14</th>
<th>D28</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. annua</td>
<td>A. afra</td>
</tr>
<tr>
<td>5–15</td>
<td>93/102 (91.2%)</td>
<td>36/51 (70.6%)</td>
</tr>
<tr>
<td>16–65</td>
<td>146/146 (100.0%)</td>
<td>145/172 (84.3%)</td>
</tr>
<tr>
<td>Overall</td>
<td>239/248 (96.4%)</td>
<td>181/223 (81.2%)</td>
</tr>
</tbody>
</table>

a N, total number within age group less any who left the trial; n, number with 0 parasitemia.

b (%) n/N x 100.
significantly greater at about 11 g/dl post treatment for *A. afr* vs. ~9 and 9.5 g/dl for ASAQ and *A. annua*, respectively. This similarity between ASAQ and *A. annua* is likely the result of artemisinin, known to reduce hemoglobin during treatment (Kurth et al., 2016). *A. afr* has but a trace of artemisinin (see Table 1 in Munyangi et al. (2018) for artemisinin content of each *Artemisia* sp. treatment) and thus, as expected, there was no decline in hemoglobin.

**ALAT and ASAT were not altered:** Although liver transaminases are often altered in malaria patients (Woodford et al., 2018), there were no significant differences observed in ALAT and ASAT among the three treatment arms (see supplemental Figure S1).

**Other studies using Artemisia tea infusions:** In China the traditional treatment against malaria is a daily dose from 4.5 to 9 g of dry leaves and twigs of *A. annua* infused in boiling water. In 1972, the Institute for Traditional Medicine of Beijing treated 31 patients with an ether extract; 20 had *P. vivax* infection, 9 had *P. falciparum*, and 2 patients had both. Fever cleared in 36 h for the *P. falciparum*-infected patients (Zhang 2005; Cui and Su 2009). In another instance, Chang and But (1986) administered 72 g of *A. annua* in an alcoholic extract over 3 d on 485 patients infected with *P. falciparum*, and on 105 patients with *P. vivax*. The cure rate was 100% against both malaria species. In 2000, Mueller et al. (2000) treated 53 DRC patients infected with *P. falciparum* using two different treatments: infusion and decoction. The posology was 5 g of dried leaves in 1 l over 5 d. The average cure rate was 92% after 4 d of treatment. In Ethiopia, Gebyaw et al. (2010) treated 73 patients suffering from uncomplicated malaria with 1 l of *A. annua* dried leaf infusion using 5 g/l per d over 7 d; 95.5% of patients were cured without adverse effects. Chougouo-Kengne et al. (2012) compared *A. annua* infusion with artesunate alone or combined with amodiaquine on 73 patients suffering from uncomplicated falciparum malaria. The posology was 5 g of dried leaf infusion in boiling water, over 5 or 7 d. The 7 d treatment improved the results from 71.3% to 100%, without any side effects. Overall, 7 d of treatment with 5 g/l *Artemisia annua* infusion seemed to provide the best therapeutic outcome.

**Synergistic effects:** In prior tea infusion studies, there was efficacy of the *A. annua* infusion against uncomplicated malaria without significant side effects. This is in line with our results showing a cure rate of 99.5% on D28 for *Artemisia* with only 5% side effects. Previously, artemisinin was considered the only active molecule, so prior studies tried to reach high levels in their preparations. Artemisinin is only present in traces in some *Artemisia* varieties and usually absent in *A. afr*. This of course raises the question of the role of artemisinin in these infusions used to treat malaria. *A. annua* and *A. afr* contain hundreds
of phytochemical molecules and minerals. Antimalarial activity has been demonstrated for some 20 of these as summarized in the review by Weathers et al. (2014). It is important to note that *A. afra* has only trace amounts of artemisinin and no detectable artemisinic parent molecules (Munyangi et al., 2018), yet almost all patients treated with that species had the same therapeutic response as those treated with *A. annua*.

**Artemisinin drug resistance:** Despite the fact that *A. annua* shows high efficacy without side effects, there has been reluctance in endorsing use of the plant. Low artemisinin content of the plant elicited concerns that this might induce artemisinin drug resistance (Blanke et al., 2008; Mueller et al., 2004; WHO, 2012). Since then rodent

---

### Table 4

<table>
<thead>
<tr>
<th>Observed adverse effect</th>
<th>Number of subjects in the Artemisia arms</th>
<th>Number of subjects in the ASAQ arm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal pain</td>
<td>0</td>
<td>25</td>
</tr>
<tr>
<td>Asthenia</td>
<td>0</td>
<td>30</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Drowsiness</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Fatty cough</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>0</td>
<td>20</td>
</tr>
<tr>
<td>Insomnia</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Nausea</td>
<td>10</td>
<td>30</td>
</tr>
<tr>
<td>Pruritus</td>
<td>0</td>
<td>35</td>
</tr>
<tr>
<td>Vertigo</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Vomiting</td>
<td>15</td>
<td>50</td>
</tr>
<tr>
<td>Total</td>
<td>25</td>
<td>210</td>
</tr>
<tr>
<td>% of total</td>
<td>5.0%</td>
<td>42.8%</td>
</tr>
</tbody>
</table>

---

Fig. 3. Average parasitemia progression among the three treatment arms. Top, graphical representation. Bottom, Kaplan–Meier; survival time of parasites started when a patient was included in the study (D0). Patients were followed until D28. For patients withdrawing from the study before D28 or still having parasites until D28, survival time is said to be censored. The censored survival rates of *A. annua*, *A. afra*, and ASAQ are 3.6%, 11.2%, and 65.7%, respectively.

Fig. 4. Microscopically determined proportion of patients with gametocytes (carriers) throughout the trial period.
studies using *per os* dried leaf *Artemisia* (DLA), Elfawal et al. (2015) demonstrated that compared to pure artesinin, DLA was threefold more resilient against evolution of artesiminin drug resistance. Furthermore, DLA even eliminated artesimin-resistant parasites in a *P. yoelli* rodent model (Elfawal et al., 2015). In humans unresponsive to either ASAQ or i.v. artesunate, *A. annua* (DLA) eliminated parasites within a few days even in comatose pediatrics (Daddy et al., 2017). Studies showed that the numerous phytochemicals in *A. annua* and *A. afra* provide synergies and multiple interactions, likely constituting a polytherapy against malaria (Elford et al., 1987; Li et al., 2018; Liu et al., 1992; Suberu et al., 2013). Together, those data and this study indicate that artesinin is not the sole phytochemical demonstrating antimalarial efficacy by *Artemisia* sp. Moreover, the presence of multiple phytochemicals in *Artemisia* sp. acts not as a mono or dual therapy, but as a poly-combination-therapy.

In the present study, we saw a large number of ASAQ failures, yet in the same localities, *A. afra* and especially *A. annua* were highly effective. If those failures are ASAQ resistance, then *Artemisia* tea infusions cured those patients. As we and others observe mounting failures of ACTs in Africa, *Artemisia annua* in particular could provide an effective and rapid alternative for holding the parasite at bay. For how long? No one knows, but lives are at risk and this is an inexpensive, safe and effective therapeutic that could be implemented rather quickly.

**Conclusion**

Treating uncomplicated malaria with either *A. annua* or *A. afra* was superior to the artesunate-amodiaquine ASAQ treatment. Fever and parasitemia clearances were faster and more efficient with both *Artemisia* species than with ASAQ; adverse effects were negligible. At D14–28 gametocyte carriage was undetectable in *Artemisia*-treated patients, so transmission to the mosquito should be interrupted. *Artemisia* is a polytherapy with at least 10 active molecules likely acting in synergy, so resistance is therefore unlikely to emerge. Plants can be grown and used by local populations, which could help counteract the problems caused by fake or obsolete antimalarial drugs. Despite these exciting results, however, it is important that further large-scale studies be launched to optimize use of these plants and posology for children, pregnant women and others, in the case of uncomplicated as well as severe malaria.

### Acknowledgments

Authors appreciate Impala Avenir Foundation, Mme Hélène de Cossé Brissac and Mr. Jean-Louis Bouchard for generously funding this study. Matthew Desrosiers, Danielle Snider, and Dr. Bruno Giroux provided valuable feedback. We are also grateful for Award Number 2NH-R15AT008277-02 from the National Center for Complementary and Integrative Health that enabled PJW and MJT to provide phytochemical analyses of the plant material used in treating these patients. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Complementary and Integrative Health or the National Institutes of Health.

### Conflict of interest

We confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this study that could have influenced its outcome.

### Supplementary materials


### References


---

**Table 5**

<table>
<thead>
<tr>
<th>Age (y)</th>
<th><em>A. annua</em> n/N (%)</th>
<th><em>A. afra</em> n/N (%)</th>
<th>ASAQ n/N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children (5–15)</td>
<td>43/43 (100%)</td>
<td>102/102 (100%)</td>
<td>111/114 (97.4%)</td>
</tr>
<tr>
<td>Adults (16–65)</td>
<td>205/205 (100%)</td>
<td>147/147 (100%)</td>
<td>369/376 (98.1%)</td>
</tr>
<tr>
<td>Total</td>
<td>248/248 (100%)</td>
<td>249/249 (100%)</td>
<td>480/490 (98.0%)</td>
</tr>
</tbody>
</table>

N, total within age group; n, number of patients with microscopically undetectable gametocytes.

**Fig. 5.** Hemoglobin levels during the first four days of treatment.